A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants

NCT06342700 | Completed Phase 1 FDA Drug

• 2 other identifiers: PKM18138U1111-1299-1906
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 1

Brief Summary

This is a cross-over, Phase 1, 4-arm study. The purpose of this study is to measure the relative bioavailability and food effect of crystalline formulation rilzabrutinib and amorphous formulation rilzabrutinib in healthy male and female participants aged 18 to 55 years of age. The total study duration per participant is expected to be up to 36 days, including:

• Screening: up to 4 weeks
• Treatment periods: once successfully screened, enrolled participants will be randomized to 1 of 4 treatment sequences with 4 single dose treatment periods.
• Washout: One day washout is planned after each treatment period hence providing 2 days between doses.
• Safety follow-up: participants will be asked to participate in an end-of-study safety assessment upon discharge from the clinical study unit, ie, on Day 8 of the study.

Conditions

Autoimmune Disorder; Healthy Volunteers

Outcome Measures

Primary Outcomes (3)

• Relative bioavailability as assessed by rilzabrutinib Cmax following administration of the test and reference formulations in the fasted state

  Cmax: maximum plasma concentration

  Day 1 to Day 8

• Relative bioavailability as assessed by rilzabrutinib AUClast following administration of the test and reference formulations in the fasted state

  AUClast: area under the plasma concentration versus time curve from time zero to the last measurable concentration

  Day 1 to Day 8

• Relative bioavailability as assessed by rilzabrutinib AUC following administration of the test and reference formulations in the fasted state

  AUC: area under the plasma concentration versus time curve extrapolated to infinity

  Day 1 to Day 8

Secondary Outcomes (7)

• Relative bioavailability as assessed by rilzabrutinib Cmax following administration of the test and reference formulations in the fed state

  Day 1 to Day 8

• Relative bioavailability as assessed by rilzabrutinib AUClast following administration of the test and reference formulations in the fed state

  Day 1 to Day 8

• Relative bioavailability as assessed by rilzabrutinib AUC following administration of the test and reference formulations in the fed state

  Day 1 to Day 8

• Food effects as assessed by rilzabrutinib Cmax following administration of the test and reference formulations under the fed versus fasted state

  Day 1 to Day 8

• Food effects as assessed by rilzabrutinib AUClast following administration of the test and reference formulations under the fed versus fasted state

  Day 1 to Day 8

Study Arms (4)

Treatment A: SAR444671 amorphous fasted

ACTIVE COMPARATOR

Participants will receive single oral dose of amorphous tablet formulation rilzabrutinib (SAR444671) under fasted conditions on Day 1 for one period

Drug: Rilzabrutinib amorphous form

Treatment B: SAR444671 crystalline fasted

EXPERIMENTAL

Participants will receive single oral dose of crystalline tablet formulation rilzabrutinib (SAR444671) under fasted conditions on Day 1 for one period

Drug: Rilzabrutinib crystalline form

Treatment C: SAR444671 amorphous fed

ACTIVE COMPARATOR

Participants will receive single oral dose of amorphous tablet formulation rilzabrutinib (SAR444671) under fed conditions on Day 1 for one period

Drug: Rilzabrutinib amorphous form

Treatment D: SAR444671 crystalline fed

EXPERIMENTAL

Participants will receive single oral dose of crystalline tablet formulation rilzabrutinib (SAR444671) under fed conditions on Day 1 for one period

Drug: Rilzabrutinib crystalline form

Interventions

Rilzabrutinib crystalline form DRUG

Pharmaceutical form:Film coated tablet Route of administration:Oral

Also known as: SAR444671

Treatment B: SAR444671 crystalline fasted; Treatment D: SAR444671 crystalline fed

Rilzabrutinib amorphous form DRUG

Pharmaceutical form:Film coated tablet Route of administration:Oral

Also known as: SAR444671

Treatment A: SAR444671 amorphous fasted; Treatment C: SAR444671 amorphous fed

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Body weight between 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, body mass index (BMI) between 18.0 and 32.0 kg/m2, inclusive
• Laboratory parameters within the normal range, unless the Investigator considers an abnormality to be clinically irrelevant for healthy participant. Hepatic transaminases (aspartate aminotransferase, alanine aminotransferase) should not exceed 1.25 × the upper laboratory norm (ULN); total bilirubin should not exceed 1 × ULN
• Willing to abstain from using tobacco or nicotine-containing products or consuming alcohol from check-in (Day -1) until discharge at end-of-study visit
• Willing to abstain from taking any prescription drugs, dietary supplements, or non-prescription drugs within 14 days or 5 half-lives, whichever, is longer, prior to the first dose of study drug through the follow-up phone call. Use of hormonal contraception and aspirin (at doses of ≤2000 mg/day) or ibuprofen (at doses of ≤1200 mg/day) are allowed prior to and during the study
• Negative urine drug/alcohol testing at screening and check-in (Day -1). Screening urine drug/alcohol testing may be repeated once if deemed appropriate by the site Investigator
• Willing to abstain from consuming grapefruit, star fruit, or Seville orange-containing products from 14 days prior to first dose of study drug until discharge from the clinical study unit

You may not qualify if:

• Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), infectious disease, or signs of acute illness
• Participant has clinical signs and symptoms consistent with COVID-19, eg, fever, dry cough, dyspnea, loss of taste and smell, sore throat, fatigue or confirmed infection by appropriate laboratory test within the last 4 weeks prior to Screening. Participant who had severe course of COVID-19 (ie, hospitalization, extracorporeal membrane oxygenation \[ECMO\], mechanically ventilated)
• Participant has a positive test result for SARS-CoV-2 (measured via Real-time Reverse Transcriptase Polymerase Chain Reaction \[RT-PCR\] or Rapid Antigen Test \[RAT\])
• Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month)
• Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in systolic blood pressure \<30 mmHg within 3 minutes when changing from supine to standing position
• Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician. Participants with known hypersensitivity to any component of the IMP formulation or allergic disease diagnosed and treated by a physician
• History or presence of drug or alcohol abuse (alcohol consumption more than 40 g per day on a regular basis)
• Regular intake of nicotine (via patch, smoking, vaping or other forms) more than 10 mg per day (based on the average nicotine content of 10-12 mg of nicotine per cigarette and inhalation of up to 2 mg of nicotine per cigarette), and unable to stop smoking during the study (occasional smoker can be enrolled)
• Excessive consumption of beverages containing xanthine bases (more than 4 cups or glasses per day)
• If female, pregnancy (defined as positive β-HCG blood test), or breast-feeding
• Non-live vaccines, including COVID-19: last administration of a vaccine within 4 weeks before randomization
• Live vaccines: last administration of a vaccine within 3 months before randomization
• Positive result on any of the following tests: hepatitis B surface antigen (HBs Ag), anti-hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab)
• Positive result on urine drug screen (amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates)
• Positive alcohol breath or alcohol urine test

Sponsors & Collaborators

• Sanofi: lead

Study Sites (1)

Nucleus Network Site Number : 8400001

Saint Paul, Minnesota, 55114, United States

Location

Related Links

• PKM18138 Plain Language Results Summary

MeSH Terms

Conditions

Autoimmune Diseases

Condition Hierarchy (Ancestors)

Immune System Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 18, 2024
• First Posted: April 2, 2024
• Study Start: March 25, 2024
• Primary Completion: April 23, 2024
• Study Completion: April 23, 2024
• Last Updated: September 3, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will share

Locations

US (1)